Atrium Therapeutics, Inc.

Atrium Therapeutics (RNA) shows no cyber incidents or material red-flag filings in the past 90 days, with no officer departures, bankruptcies, or restatements detected. However, low signal in our monitoring window does not indicate comprehensive risk—biotech firms face structural dilution exposure and financing volatility that require deeper context. The full $49 Report extends analysis across 12 months of SEC filings, calculates shareholder dilution risk scores, maps financing history and burn rate trends, and flags AI-detected anomalies in MD&A language and officer trading patterns. The full $49 Report adds quantified dilution risk, 12-month red-flag context, and forward financing pressure signals.